HSV Vectors with NF-kB Response Elements for Cancer Stem Cell Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses, such as HSV-1, face challenges in effectively replicating within cancer cells, particularly in cancer stem cells, which are resistant to oncolysis, limiting their therapeutic efficacy.
Innovation Solution
Incorporating NF-κB and Oct3/4-SOX2 response elements into the regulatory regions of viral genes like US11, ICP4, ICP27, and ICP8 to enhance viral replication by making the viral genes responsive to activation in cancer cells, along with encoding therapeutic substances like IL12, IL15, OX40L, or PD-1 blockers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oncolytic viruses are used to treat cancer, then some cancer cells are killed through viral replication, but the viruses fail to effectively replicate in cancer stem cells and treatment-resistant cancer cells
Solution Approach 1:
The patent introduces response elements that are specifically activated by transcription factors present in cancer stem cells and treatment-resistant cells (NF-κB, Oct3/4, SOX2) into the regulatory regions of viral genes. This creates local specificity in gene expression, allowing the virus to adapt its replication capability to different cancer cell types based on their unique molecular characteristics rather than using a uniform approach.
Solution Approach 2:
The patent modifies the regulatory regions of viral genes by incorporating specific response elements that change the expression parameters of viral genes in response to cancer cell-specific transcription factors. This allows the virus to dynamically adjust its replication efficiency based on the molecular environment of different cancer cells, transforming a static viral system into one that can adapt to varying cellular conditions.
2Productivity
If viral replication is enhanced in cancer cells through response elements, then oncolytic activity increases, but the complexity of the viral vector increases
Solution Approach 1:
The patent pre-installs response elements into the regulatory regions of viral genes during vector construction. These elements are positioned in advance to be activated by cancer cell-specific transcription factors, allowing the virus to automatically enhance its replication productivity upon encountering target cells without requiring additional external activation steps or complex control mechanisms during treatment.
Data Source
Figure 1A~1B
Figure 2
Figure 3A
AI summary
An oncolytic HSV vector comprising an NF-κΒ response element or an Oct-3/4-SOX2 response element in a regulatory region of a viral gene that affects viral replication efficiency.